Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

This study evaluated the efficacy and safety of a 5% minoxidil topical foam without propylene glycol in men with androgenic alopecia.

This study found that a bleach bath treatment with 0.005% HOCI reduced the expression of certain serine proteases in cultured keratinocytes and lowered skin pH in atopic dermatitis patients, potentially improving symptoms by modulating the NF-kB pathway.

This study found that 5% minoxidil topical foam used once daily for 24 weeks was well tolerated and significantly improved hair regrowth and scalp coverage in women with female pattern hair loss compared to vehicle foam.

This study reported that using 5% minoxidil topical foam twice daily improved hair density and width in both the frontotemporal and vertex regions of men with moderate androgenetic alopecia.

This case report describes a 66-year-old man with frontal fibrosing alopecia, a rare lichen planopilaris variant, presenting with scarring alopecia at the hairline and extensive body hair loss.

This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.

Certain hairstyles can cause scalp diseases, smoking is linked to hair loss, 5% minoxidil foam is effective for hair loss treatment, and various factors influence wound healing and hair growth.

This study found that platelet-rich plasma was effective for hair regrowth in women with androgenic alopecia, though less so than minoxidil, but it was associated with improved quality of life responses.

This study found that 5% topical minoxidil was moderately more effective at increasing hair regrowth than 10% minoxidil and placebo in men with androgenetic alopecia.

This abstract discusses platelet-rich plasma therapy for patterned hair loss but provides no new clinical results, suggesting further research is needed to determine its effectiveness.

This study found that women with androgenetic alopecia using 5% minoxidil daily reported high satisfaction and improved quality of life, despite the continued impact of hair loss on daily habits and social life.

This study observed that while both minoxidil and botanically-derived 5-alpha reductase inhibitors significantly increased hair count and diameter in women with female pattern hair loss, minoxidil was more effective, especially for greater hair diameter increases, but had more troublesome side effects.

This study reported that sulfotransferase activity in plucked hair follicles can predict treatment response to 5% topical minoxidil in women with androgenetic alopecia with high sensitivity and specificity.

This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.

This case report describes a non-arteritic anterior ischemic optic neuropathy that resolved after discontinuing topical 5% minoxidil treatment.

This study found that combining low-level light therapy with topical minoxidil 5% may lead to better hair regrowth and patient satisfaction in treating female pattern hair loss compared to using each treatment alone.

Recent Phase III trials reported that once daily 5% minoxidil foam significantly increased hair count in women with female pattern hair loss and was shown to be as effective as twice daily 2% minoxidil solution.

This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

This study developed a nanoemulsion containing Minoxidil, which showed effective stability and significantly increased hair growth rates in pretreated mice, suggesting its potential for treating hair loss.

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This study found that a minoxidil foamable emu oil emulsion significantly promoted hair growth in animals compared to a marketed 5% minoxidil solution, showing increased hair follicles in the anagenic phase.

This review discusses topical and intralesional treatments for alopecia areata, providing a management strategy based on patient age and disease severity, but reports no new clinical results.

This review discusses clinical features, differential diagnosis, and treatments for female pattern hair loss, emphasizing the use of 2% topical Minoxidil and exploring alternative off-label therapies.

This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.

This review article reports recent advancements in understanding, diagnosing, and treating various hair loss conditions, like androgenetic alopecia and alopecia areata, including their genetic factors and new therapeutic options, while also examining the impact of COVID-19 on hair loss.

This article reviews the clinical assessment of female pattern hair loss and discusses up-to-date treatments, highlighting oral minoxidil combined with oral spironolactone as a promising novel therapy. It emphasizes the crucial role of general practitioners in diagnosis, treatment planning, and managing associated psychosocial issues.

This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.